REG - Destiny Pharma PLC - Notice of Full Year Results

Destiny PharmaAnnouncement

08/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH5895Ja&default-theme=true

RNS Number : 5895J  Destiny Pharma PLC  08 April 2024

08 April 2024

 

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Notice of Full Year Results and Investor Presentation

 

Brighton, United Kingdom - Destiny Pharma plc (AIM: DEST), a clinical stage
innovative biotechnology company focused on the development of novel medicines
that can prevent life threatening infections, will announce its financial
results for the year ended 31 December 2023, on Thursday 25 April 2024.

 

Chris Tovey, Chief Executive Officer, and Shaun Claydon, Chief Financial
Officer, will host a briefing for analysts at 8.30am BST followed by a
presentation to all existing and potential shareholders at 11:00am BST held
via the Investor Meet Company platform. Further details for the analyst
briefing will be shared by invitation in due course.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard
up until 09:00am BST the day before the meeting, or at any time during the
live presentation.

 

Investors can sign up to Investor Meet Company for free, and add to meet
Destiny Pharma

plc via:
https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://www.investormeetcompany.com/destiny-pharma-plc/register-investor)

 

Investors who already follow Destiny Pharma plc on the Investor Meet Company
platform will automatically be invited.

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

 

FTI Consulting

Ben Atwell / Simon Conway / Michael Trace

+44 (0) 203 727 1000

destinypharma@fticonsulting.com

 

Shore Capital (Nominated Advisor and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused
on the development and commercialisation of novel medicines that can prevent
life-threatening infections. The company's drug development pipeline includes
two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical staphylococcal
hospital infections including MRSA.

 

For further information on the company, please visit www.destinypharma.com
(http://www.destinypharma.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKDLFBZZLFBBF